Compare LQDA & HGV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LQDA | HGV |
|---|---|---|
| Founded | 2004 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.3B |
| IPO Year | 2020 | 2017 |
| Metric | LQDA | HGV |
|---|---|---|
| Price | $37.80 | $49.09 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 8 |
| Target Price | $41.00 | ★ $52.13 |
| AVG Volume (30 Days) | ★ 1.1M | 709.8K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 51.81 | ★ 97.78 |
| EPS | N/A | ★ 0.89 |
| Revenue | $158,320,000.00 | ★ $5,047,000,000.00 |
| Revenue This Year | $278.87 | $25.30 |
| Revenue Next Year | $57.13 | $1.98 |
| P/E Ratio | ★ N/A | $55.01 |
| Revenue Growth | ★ 1031.18 | 1.33 |
| 52 Week Low | $11.85 | $32.29 |
| 52 Week High | $46.67 | $52.08 |
| Indicator | LQDA | HGV |
|---|---|---|
| Relative Strength Index (RSI) | 49.78 | 67.67 |
| Support Level | $31.75 | $41.93 |
| Resistance Level | $39.19 | $51.53 |
| Average True Range (ATR) | 2.12 | 1.62 |
| MACD | 0.09 | 0.92 |
| Stochastic Oscillator | 37.52 | 97.81 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
Hilton Grand Vacations Inc is a timeshare company engaged in developing, marketing, selling, managing, and operating timeshare resorts and timeshare plans under the Hilton Grand Vacations brand. The company operates in two segments: Real estate sales and financing, and Resort operations and club management. The Real estate sales and financing segment generates revenue from VOI sales and consumer financing, including interest income from loans to members. The Resort operations and club management segment generates revenue from resort management services, club membership fees, and rental of available inventory. The majority of the company's revenue is earned through the Real estate sales and financing segment.